KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Change in Account Payables (2016 - 2022)

Inovio Pharmaceuticals' Change in Account Payables history spans 13 years, with the latest figure at $859354.0 for Q1 2022.

  • For Q1 2022, Change in Account Payables rose 585.88% year-over-year to $859354.0; the TTM value through Mar 2022 reached $639125.0, down 12.11%, while the annual FY2021 figure was -$94937.0, 169.99% down from the prior year.
  • Change in Account Payables for Q1 2022 was $859354.0 at Inovio Pharmaceuticals, up from $56387.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.0 million in Q2 2021 and bottomed at -$1.3 million in Q3 2021.
  • The 5-year median for Change in Account Payables is $125292.0 (2021), against an average of $41344.3.
  • The largest annual shift saw Change in Account Payables plummeted 553.11% in 2021 before it soared 585.88% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at $286872.0 in 2018, then fell by 6.88% to $267133.0 in 2019, then crashed by 156.89% to -$151959.0 in 2020, then soared by 137.11% to $56387.0 in 2021, then skyrocketed by 1424.03% to $859354.0 in 2022.
  • Per Business Quant, the three most recent readings for INO's Change in Account Payables are $859354.0 (Q1 2022), $56387.0 (Q4 2021), and -$1.3 million (Q3 2021).